Ernexa Highlights ERNA-101’s Dual IL-7/IL-15 iMSC Platform for Scalable Ovarian Cancer Therapy
ERNA•Ernexa Therapeutics highlighted the significant unmet need in ovarian cancer treatment, emphasizing ERNA-101’s dual IL-7/IL-15 fusokine-iMSC platform designed to remodel tumor microenvironments and activate immune responses in immunologically “cold” tumors. The company showcased scalable, off-the-shelf manufacturing advantages to expand patient access compared to autologous approaches.
1. Virtual Investor KOL Connect Segment
Ernexa Therapeutics hosted a virtual investor KOL connect segment featuring Dr. Ira S. Winer, a gynecologic oncologist and Scientific Advisory Board member, to discuss challenges in ovarian cancer treatment and the company’s development programs.
2. Ovarian Cancer Unmet Need and Cold Tumors
Dr. Winer emphasized the significant unmet need for effective therapies in later-line ovarian cancer, highlighting the prevalence of immunologically “cold” tumors that resist current immune-based treatments and limit patient outcomes.
3. ERNA-101 Dual Mechanism Platform
The company detailed its lead candidate ERNA-101, an engineered IL-7/IL-15 fusokine-iMSC therapy designed to remodel the tumor microenvironment and activate immune responses, aiming to convert non-responsive tumors into more treatable ones.
4. Manufacturing Scalability and Accessibility
Ernexa also outlined its allogeneic iMSC manufacturing approach, which allows for off-the-shelf production, potentially reducing costs and improving patient access compared to complex autologous cell therapies.
